Quantcast
Last updated on April 21, 2014 at 11:58 EDT

Latest Olaparib Stories

2010-04-06 08:15:00

WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market -- driven by the approval and rapid uptake of Roche/Genentech/Chugai's Avastin -- will more than triple from $449 million in 2008 to just under $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings from the topic...

2010-04-06 07:21:26

Women with breast cancer before age 55 who carry an inherited mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite, or contralateral, to their initial tumor as compared to breast cancer patients without these genetic defects. These findings, by Fred Hutchinson Cancer Research Center breast cancer epidemiologist Kathleen Malone, Ph.D., and colleagues, were published online April 5 in the Journal of Clinical...

2010-02-24 07:00:00

WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, Sanofi-Aventis's BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Owing to the improvement in overall survival rates it has demonstrated in clinical trials and the need for novel targeted...

2010-02-22 13:18:34

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports. Susan Bates and Christina Annunziata looked at several recent papers on this form of treatment, which takes advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy...

2010-01-25 15:15:20

Breast cancer patients who have triple negative breast cancer, an aggressive form of the disease, that has spread to other parts of the body, are being asked to participate in a clinical study of a promising new treatment called PARP inhibitors. Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine will conduct the study at both the Baylor Clinic and the Harris County Hospital District's Ben Taub General Hospital. "This is a very important study," said Dr....

2009-12-19 00:15:25

New findings may help explain why women who carry a mutated BRCA1 gene have greater rates of infertility as well as a greater risk for breast and ovarian cancer A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility. In a paper published last week in the Journal of Clinical Oncology, Kutluk Oktay, M.D., professor of obstetrics and gynecology...

2009-11-09 07:00:00

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new...

2009-11-05 12:58:37

Selective eradication of malignant cells The ultimate goal in cancer research, a treatment that kills cancer cells whilst leaving healthy cells untouched, is brought nearer by the success of a new therapeutic approach. The potential therapy, published in BioMed Central's open access journal Breast Cancer Research, targets proliferation of cancer, but not normal, cells. An international research team led by Professor Cohen-Armon of Tel-Aviv University found that potent phenanthridine derived...

2009-09-22 07:41:15

Women with mutations in either their BRCA1 or BRCA2 genes have a dramatically increased risk of developing breast or ovarian cancer. Identifying such women provides them with an opportunity to take preventive measures such as surgery to remove their breasts. One caveat to identifying such women by simply sequencing their BRCA1 and BRCA2 genes and detecting mutations is that not all mutations are harmful. However, Shyam Sharan and colleagues, at the National Cancer Institute at Frederick, have...

2009-01-30 09:28:11

 Men who develop prostate cancer face an increased risk of having an aggressive tumor if they carry a so-called breast cancer gene mutation, scientists from the Albert Einstein College of Medicine of Yeshiva University report in today's issue of Clinical Cancer Research. The findings could help to guide prostate-cancer patients and their physicians in choosing treatment options.The study, involving 979 men with prostate cancer and 1251 men without the disease, looked at whether...